But does it cost too much?

Telix Pharmaceuticals (NASDAQ:TLX) executives highlighted commercial momentum in prostate cancer imaging and outlined multiple clinical programs in oncology during an H.C. Wainwright discussion ...

"This technology gives us a powerful tool to detect prostate cancer earlier and more precisely,” said Dr. James Howard.

Tagawa, MD, identified 3 primary clinical scenarios where PSMA PET scans have become the established standard for prostate cancer care. The first application is initial s ...

Researchers presented clinical study results on the dual-tracer PET imaging technique at the European urology conference with peer-reviewed publication forthcoming.

FDA approves Pylarify TruVu, a new prostate cancer PET imaging agent designed to expand access and improve detection of recurrent or metastatic disease.

LOS ANGELES (KABC) -- New technology that's allowing doctors to pinpoint prostate cancer long before it becomes a threat is now widely available. A former firefighter mentioned how this new imaging ...

Researchers in Denmark conducted a prospective single-centre study including 160 patients with newly diagnosed high-risk prostate cancer between 2021 and 2024. All the participants first underwent an ...

Surgery patients staged with PSMA-PET appear to have a lower risk of early BCR than those staged with conventional imaging. Early oncologic outcomes after radical prostatectomy (RP) for very high risk ...

A new radioactive diagnostic agent for use in prostate cancer has been approved by the US Food and Drug Administration (FDA). The product, Gallium 68 PSMA-11 (Ga 68 PSMA-11), has been approved for ...